Cuba is going through the worst wave of contagion from the beginning pandemic, with the peak reached on 21 June of 1,561 new cases and 11 new ones deaths. But at the same time the health authorities of the island, through the newspaper of the Communist Party, Granma, announce that the vaccine Abdala, developed by the Center for Genetic Engineering and Biotechnology (Cigb), has a three-dose efficacy of 92.28%. This is the second serum to arrive in Phase 3 in Havana after Soberana 02, which with two doses reached an efficacy of 62%. But a Cuba there are two other anti-Covid antidotes being tested: Sovereign 01 e Mambisa.
The Cuban president Miguel Diaz-Canel stressed that “in 13 months the researchers of the Cigb they have reached a global milestone and are working towards an even more important success ”. The newspaper for its part recalls that with its 92.28% effectiveness “Abdala far exceeds the minimum requirement set by the World Health Organization (WHO) for vaccines against Covid-19 is 50% “. Diaz-Canel he also stressed that “in the 48 hours that passed from Saturday to Monday Cuba, A poor and small country, has shaken the world ”announcing the success of experimentation of two vaccines, the Sovereign 02, which with two doses has reached an efficacy of 62%, and now Abdala. The Cuban head of state met the researchers on Saturday of the Institute Finlay who had explained to him how the two doses of the vaccine Sovereign 02, which has finished testing phase 3, will be supplemented by a reinforcement of a third dose of Sovereign Plus which should place it among the most effective vaccines for controlling the virus Sars-CoV-2. The general director of the Cigb, Marta Ayala µvila, pointed out that the final analysis of the efficacy studies of Abdala conducted by an independent group includes not only the response to an initial strain of Sars-CoV-2 (DG614G), but also mutants Alpha, Beta and Gamma.
As for Soberana02 the national body BioCubaFarma who participates in the development of the drug explained that the figure of 62% is the result of the step 3 of experimentation on 44,010 volunteers divided into three study groups, two experimental and one with a placebo control. “It is already compliant with the conditions of a vaccine, but its emergency use will only be authorized by the Cecmed (Center for State Control of Medicines, Equipment and Medical Devices), ”Diaz-Canel pointed out on Twitter.
(in the photo the Cuban epidemiological institute Finlay which produces the Soberana 02)